This was the stock's third consecutive day of gains.

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors , nivolumab and relatlimab ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Bristol Myers Squibb outperformed major indexes, closing 1.32% higher at $47.66, while peers lagged. The company’s stock ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $47.66, marking a +1.32% move from the previous day. This change outpaced the S&P 500's 0.61% gain on the day. Elsewhere, the Dow ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...